Neuralink is set to conduct its second procedure after receiving clearance from the FDA. Following the successful implantation of the device in Noland Arbaugh, the first patient to undergo the procedure, Neuralink is now poised to implant its device into another patient's brain.
(Photo: Screenshot from Neuralink Youtube Page)
Receiving FDA Clearance
The Food and Drug Administration (FDA) has granted clearance for Neuralink to implant its brain chip in a second patient. This decision follows the company's reported efforts to address issues with electrode functionality that had limited the device's effectiveness in its initial human test subject.
This marks another stride in the advancement of brain-computer interface technology, which holds promise for treating neurological disorders in the future.
Neuralink, a venture by Elon Musk, has announced its search for another patient suffering from quadriplegia to participate in testing the device's capabilities, such as controlling electronic devices like phones and computers.
According to sources cited by the Wall Street Journal, Neuralink has proposed solutions that involve embedding certain wiring components of the device deeper into the brain, aiming to enhance its performance and reliability.
Neuralink initiated the recruitment process for its first clinical trial last year, aiming to introduce the technology to individuals with conditions such as ALS, spinal cord injuries, or quadriplegia.
Neuralink has informed the FDA of its plan to conduct a second procedure, during which it intends to implant the device's threads deeper into the patient's brain. This adjustment aims to minimize the movement of the threads, addressing the issue observed in Arbaugh's case.
The FDA has reportedly approved these proposed changes. The company aims to carry out the second surgery in June and has garnered significant interest, with over 1,000 individuals signing up for the opportunity to participate in the trial.
However, software updates have been implemented to restore many lost functionalities. Complications arose within a month of the surgery when several hairlike threads implanted in his brain became dislodged. This disruption prevented the device from effectively interpreting most electrical signals that translate his thoughts into actions.
Despite this setback, approximately 15% of the threads remained intact and eventually stabilized. With the aid of software modifications, Arbaugh managed to regain many of the device's functionalities.
Neuralink has released video clips showcasing Arbaugh, who suffers from paralysis from the neck down, engaging in various activities such as playing chess, operating a music player app, and other tasks. Arbaugh shared his experience with the Neuralink device, expressing how it has granted him near-complete control over a computer solely through his thoughts.
